EcoDrugPlus

60s Ribosomal Protein L19

Ensembl ID : ENSFHEG00000015527
Gene Symbol: LOC105939963
4 Cross references
338 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSFHEG00000017368
Gene Symbol: LOC105921030
3 Cross references
383 Possible Orthologues:

60s Ribosomal Protein L26

Ensembl ID : ENSFHEG00000007399
Gene Symbol: LOC105931547
3 Cross references
460 Possible Orthologues:

60s Ribosomal Protein L27a-Like

Ensembl ID : ENSFHEG00000012029
Gene Symbol: LOC105918681
2 Cross references
509 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSFHEG00000018524
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSFHEG00000014812
Gene Symbol: ADAM17
3 Cross references
210 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSFHEG00000020158
Gene Symbol: ADAMTS5
4 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSFHEG00000005257
Gene Symbol: ADRM1
3 Cross references
193 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSFHEG00000008588
Gene Symbol: AKT1
3 Cross references
196 Possible Orthologues:

Atp Binding Cassette Subfamily B Member 1

Ensembl ID : ENSFHEG00000000330
Gene Symbol: ABCB1
4 Cross references
163 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSFHEG00000010183
Gene Symbol: ABCC1
3 Cross references
203 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSFHEG00000011313
Gene Symbol: ABCC8
3 Cross references
227 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).